## CLAIMS

WHAT IS CLAIMED IS:

1. At least one compound selected from compounds of Formula I:



I

stereoisomers thereof, and pharmaceutically acceptable salts thereof,

wherein:

Q is selected from C and N;

W is selected from C and N;

X is selected from $CH_2$ and O;

Y is selected from $NR^{12}$, O, and S;

Z is selected from O, S, $NR^{13}$, CO, SO, $SO_2$, and $CR^{13}R^{14}$;

$R^1$, $R^2$, $R^3$, $R^4$, $R^5$, and $R^6$, which may be the same or different, are each selected from hydrogen, halogen, haloalkyl, alkyl, alkenyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, alkynyl, -CN, $-NR^{13}R^{14}$, $-OR^{13}$, $-COR^{13}$, $-CO_2R^{13}$, $-CONR^{13}R^{14}$, $-C(=NR^{13})NR^{14}R^{15}$, $-NR^{13}COR^{14}$, $-NR^{13}CONR^{14}R^{15}$, $-NR^{13}CO_2R^{14}$, $-SO_2R^{13}$, $-NR^{13}SO_2NR^{14}R^{15}$, $-NR^{13}SO_2R^{14}$, and $-NR^{13}SO_2$aryl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heteroaryl, aryl, and heterocyclyl are optionally substituted with at least one substituent $R^{16}$, or ($R^1$ and $R^2$), and /or ($R^3$ and $R^4$), and /or ($R^5$ and $R^6$), together with the ring to which they are attached, form a fused ring selected from heterocyclyl, and heteroaryl rings optionally substituted with at least one substituent $R^{16}$; provided that $R^1$ is absent when Q is N, and $R^5$ is absent when W is N;

$R^7$ is selected from hydrogen, halogen, alkyl, -O-alkyl, and -S-alkyl;

$R^{12}$ is selected from hydrogen and alkyl;

$R^{13}$, $R^{14}$ and $R^{15}$, which may be the same or different, are each selected from H, haloalkyl, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl; or ($R^{13}$ and $R^{14}$), and /or ($R^{14}$ and $R^{15}$) together with the atom(s) to which they are attached, each form a ring selected from heterocyclyl, and heteroaryl rings optionally substituted with at least one substituent $R^{16}$;

$R^{16}$ is selected from halogen, haloalkyl, alkyl, alkenyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, alkynyl, oxo, -CN, -OR', -NR'R", -COR', $-CO_2R'$, -CONR'R", -C(=NR')NR"R'", -NR'COR", -NR'CONR'R", $-NR'CO_2R"$, $-SO_2R'$, $-SO_2$aryl, $-NR'SO_2NR"R'"$, $NR'SO_2R"$, and $-NR'SO_2$aryl, wherein R', R", and R'" are independently selected from H, haloalkyl, alkyl, alkenyl,

alkynyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl, or (R' and R"), and /or (R" and R'") together with the atoms to which they are attached, form a ring selected from heterocyclyl, and heteroaryl rings.

2. The at least one compound of claim 1, which is selected from compounds of Formula (II)



II

stereoisomers thereof, and pharmaceutically acceptable salts thereof,

wherein:

Q is selected from C and N;

X is selected from $CH_2$ and O;

Y is selected from $NR^{12}$, O, and S;

Z is selected from O, S, $NR^{13}$, CO, SO, $SO_2$, and $CR^{13}R^{14}$;

$R^1$, $R^2$, $R^3$, $R^4$, $R^8$, $R^9$, $R^{10}$ and $R^{11}$, which may be the same or different, are each selected from hydrogen, halogen, haloalkyl, alkyl, alkenyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, alkynyl, -CN, $-NR^{13}R^{14}$, $-OR^{13}$, $-COR^{13}$, $-CO_2R^{13}$, $-CONR^{13}R^{14}$, $-C(=NR^{13})NR^{14}R^{15}$, $-NR^{13}COR^{14}$, $-NR^{13}CONR^{14}R^{15}$, $-NR^{13}CO_2R^{14}$, $-SO_2R^{13}$, $-NR^{13}SO_2NR^{14}R^{15}$, and $-NR^{13}SO_2R^{14}$, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heteroaryl, aryl, and heterocyclyl are each optionally substituted with at least one substituents $R^{16}$, or ($R^1$ and $R^2$), and /or ($R^3$ and $R^4$), and /or ($R^8$ and $R^9$), and /or ($R^9$ and $R^{10}$), and /or ($R^{10}$ and $R^{11}$) together with the ring to which they are attached, form a fused ring selected from heterocyclyl, and heteroaryl rings optionally substituted with at least one substituent $R^{16}$; provided that $R^1$ is absent when Q is N;

$R^7$ is selected from hydrogen, halogen, alkyl, -O-alkyl, and -S-alkyl;

$R^{12}$ is selected from hydrogen and alkyl;

$R^{13}$, $R^{14}$ and $R^{15}$, which may be the same or different, are each selected from H, haloalkyl, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl; or ($R^{13}$ and $R^{14}$), and /or ($R^{14}$ and $R^{15}$) together with the atom(s) to which they are attached, each form a ring selected from heterocyclyl, and heteroaryl rings optionally substituted with at least one substituent $R^{16}$;

$R^{16}$ is selected from halogen, haloalkyl, alkyl, alkenyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, alkynyl, oxo, -CN, -OR', -NR'R", -COR', $-CO_2R'$, -CONR'R", -C(=NR')NR"R'", -NR'COR", -NR'CONR'R", $-NR'CO_2R"$, $-SO_2R'$, $-SO_2$aryl, $-NR'SO_2NR"R'"$, $NR'SO_2R"$, and -

$NR'SO_2aryl$, wherein R', R", and R'" are independently selected from H, haloalkyl, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl, or (R' and R"), and /or (R" and R'") together with the atoms to which they are attached, form a ring selected from heterocyclyl, and heteroaryl rings.

3. The at least one compound of claim 1, which is selected from compounds of Formula (III)



III,

stereoisomers thereof, and pharmaceutically acceptable salts thereof,

wherein:

X is selected from $CH_2$ and O;

Z is selected from O, S, $NR^{13}$, CO, SO, $SO_2$, and $CR^{13}R^{14}$;

A is selected from $-CH_2-$, $-CH_2CH_2-$, -CH=CH-, =CH-, $-NR^{13}-$, $-CH_2-O-$, -O-, and -S-;

M is selected from =CH- and -C(O)-; or M is absent;

$R^1$, $R^2$, $R^8$, $R^9$, $R^{10}$ and $R^{11}$, which may be the same or different, are each selected from hydrogen, halogen, halo-alkyl, alkyl, alkenyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, alkynyl, -CN, $-NR^{13}R^{14}$, $-OR^{13}$, $-COR^{13}$, $-CO_2R^{13}$, $-CONR^{13}R^{14}$, $-C(=NR^{13})NR^{14}R^{15}$, $-NR^{13}COR^{14}$, $-NR^{13}CONR^{14}R^{15}$, $-NR^{13}CO_2R^{14}$, $-SO_2R^{13}$,$-SO_2aryl$, $-NR^{13}SO_2NR^{14}R^{15}$, and $-NR^{13}SO_2R^{14}$, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heteroaryl, aryl, and heterocyclyl are each optionally substituted with at least one substituent $R^{16}$,

or ($R^1$ and $R^2$), and /or ($R^8$ and $R^9$), and /or ($R^9$ and $R^{10}$), and /or ($R^{10}$ and $R^{11}$) together with the ring to which they are attached, form a fused ring selected from heterocyclyl, and heteroaryl rings optionally substituted with at least one substituent $R^{16}$;

$R^{12}$ is selected from hydrogen and alkyl;

$R^{13}$, $R^{14}$ and $R^{15}$, which may be the same or different, are each selected from H, haloalkyl, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl; or ($R^{13}$ and $R^{14}$), and /or ($R^{14}$ and $R^{15}$) together with the atom(s) to which they are attached, each form a ring selected from heterocyclyl, and heteroaryl rings optionally substituted with at least one substituent $R^{16}$;

$R^{16}$ is selected from halogen, haloalkyl, alkyl, alkenyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, alkynyl, oxo, -CN, -OR', -NR'R", -COR', $-CO_2R'$, -CONR'R", -C(=NR')NR"R'", -NR'COR", -NR'CONR'R", $-NR'CO_2R"$, $-SO_2R'$, $-SO_2aryl$, $-NR'SO_2NR"R'"$, $NR'SO_2R"$, and -

$NR'SO_2$aryl, wherein R', R", and R'" are independently selected from H, haloalkyl, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl, or (R' and R"), and /or (R" and R'") together with the atoms to which they are attached, form a ring selected from heterocyclyl, and heteroaryl rings.

4. The at least one compound of claim 1, which is selected from compounds of Formula (IV)



IV,

stereoisomers thereof, and pharmaceutically acceptable salts thereof,

wherein:

B is selected from $CH_2$, O, and $NR^{13}$;

X is selected from $CH_2$ and O;

$R^1$, $R^2$, $R^8$, $R^9$, $R^{10}$ and $R^{11}$, which may be the same or different, are each selected from hydrogen, halogen, haloalkyl, alkyl, alkenyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, alkynyl, -CN, $-NR^{13}R^{14}$, $-OR^{13}$, $-COR^{13}$,$-CO_2R^{13}$, $-CONR^{13}R^{14}$,$-C(=NR^{13})NR^{14}R^{15}$, $-NR^{13}COR^{14}$, $-NR^{13}CONR^{14}R^{15}$, $-NR^{13}CO_2R^{14}$, $-SO_2R^{13}$,$-SO_2$aryl, $-NR^{13}SO_2NR^{14}R^{15}$, and $-NR^{13}SO_2R^{14}$,wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heteroaryl, aryl, and heterocyclyl are each optionally substituted with at least one substituent $R^{16}$, or ($R^1$ and $R^2$), and /or ($R^8$ and $R^9$), and /or ($R^9$ and $R^{10}$), and /or ($R^{10}$ and $R^{11}$) together with the ring to which they are attached, form a fused ring selected from heterocyclyl, and heteroaryl rings optionally substituted with at least one substituent $R^{16}$;

$R^{12}$ is selected from hydrogen and alkyl;

$R^{13}$, $R^{14}$ and $R^{15}$, which may be the same or different, are each selected from H, haloalkyl, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl; or ($R^{13}$ and $R^{14}$), and /or ($R^{14}$ and $R^{15}$) together with the atom(s) to which they are attached, each form a ring selected from heterocyclyl, and heteroaryl rings optionally substituted with at least one substituent $R^{16}$;

$R^{16}$ is selected from halogen, haloalkyl, alkyl, alkenyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, alkynyl, oxo, -CN, -OR', -NR'R", -COR', $-CO_2R'$, -CONR'R", -C(=NR')NR"R'", -NR'COR", -NR'CONR'R", $-NR'CO_2R"$, $-SO_2R'$, $-SO_2$aryl, $-NR'SO_2NR"R'"$, $NR'SO_2R"$, and $-NR'SO_2$aryl, wherein R', R", and R'" are independently selected from H, haloalkyl, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl, or (R' and R"), and /or (R" and R'")

together with the atoms to which they are attached, form a ring selected from heterocyclyl, and heteroaryl rings.

5. The at least one compound of claim 1, which is selected from compounds of Formula (V)



V,

stereoisomers thereof, and pharmaceutically acceptable salts thereof,

wherein:

X is selected from $CH_2$ and O;

$R^8$, $R^9$, $R^{10}$ and $R^{11}$, which may be the same or different, are each selected from hydrogen, halogen, alkyl, alkenyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, alkynyl, $-NR^{13}R^{14}$, $-OR^{13}$, $-COR^{13}$, $-CO_2R^{13}$, $-CONR^{13}R^{14}$, $-C(=NR^{13})NR^{14}R^{15}$, $-NR^{13}COR^{14}$, $-NR^{13}CONR^{14}R^{15}$, $-NR^{13}CO_2R^{14}$, $-SO_2R^{13}$,$-SO_2$aryl, $-NR^{13}SO_2NR^{14}R^{15}$, and $-NR^{13}SO_2R^{14}$, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heteroaryl, aryl, and heterocyclyl are each optionally substituted with at least one substituent $R^{16}$, or ($R^8$ and $R^9$), and /or ($R^9$ and $R^{10}$), and /or ($R^{10}$ and $R^{11}$) together with the ring to which they are attached, form a fused ring selected from heterocyclyl, and heteroaryl rings optionally substituted with at least one substituent $R^{16}$;

$R^{13}$, $R^{14}$ and $R^{15}$, which may be the same or different, are each selected from H, haloalkyl, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl; or ($R^{13}$ and $R^{14}$), and /or ($R^{14}$ and $R^{15}$) together with the atom(s) to which they are attached, each form a ring selected from heterocyclyl, and heteroaryl rings optionally substituted with at least one substituent $R^{16}$;

$R^{16}$ is selected from halogen, haloalkyl, alkyl, alkenyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, alkynyl, oxo, -CN, -OR', -NR'R", -COR', $-CO_2$R', -CONR'R", -C(=NR')NR"R'", -NR'COR", -NR'CONR'R", $-NR'CO_2$R", $-SO_2$R', $-SO_2$aryl, $-NR'SO_2NR"R'"$, $NR'SO_2R"$, and $-NR'SO_2$aryl, wherein R', R", and R'" are independently selected from H, haloalkyl, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl, or (R' and R"), and /or (R" and R'") together with the atoms to which they are attached, form a ring selected from heterocyclyl, and heteroaryl rings.

6. At least one compound selected from the following compounds:

































stereoisomers thereof, and pharmaceutically acceptable salts thereof.

7. Theat least one compoundof claim 1, having a Raf-inhibiting activity corresponding to aIC$_{50}$ of 10 μM or less in a Raf enzyme assay.

8. A pharmaceutical composition comprising at least one pharmaceutically acceptable carrier and as an active ingredient a therapeutically effective amount of at least one compound of claim 1.

9. A method of treatingcancer responsive to inhibition of Raf kinase comprising administering to a subject in recognized need thereof at least one compound of any one of claims 1-6 in an amount effective to inhibit said Raf kinase.

10. A method for making a medicament for inhibiting the activity of Raf kinase, comprising including into the medicament at least one compound of any one of claims 1-6.

## CLAIMS

1. At least one compound selected from compounds of Formula (I):



(I)

stereoisomers thereof, and pharmaceutically acceptable salts thereof,

wherein:

Q is selected from C and N;

W is selected from C and N;

X is selected from $CH_2$ and O;

Y is selected from $NR^{12}$, O, and S;

Z is selected from O, S, $NR^{13}$, CO, SO, $SO_2$, and $CR^{13}R^{14}$;

$R^1$, $R^2$, $R^3$, $R^4$, $R^5$, and $R^6$, which may be the same or different, are each selected from hydrogen, halogen, haloalkyl, alkyl, alkenyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, alkynyl, -CN, $-NR^{13}R^{14}$, $-OR^{13}$, $-COR^{13}$, $-CO_2R^{13}$, $-CONR^{13}R^{14}$, $-C(=NR^{13})NR^{14}R^{15}$, $-NR^{13}COR^{14}$, $-NR^{13}CONR^{14}R^{15}$, $-NR^{13}CO_2R^{14}$, $-SO_2R^{13}$, $-NR^{13}SO_2NR^{14}R^{15}$, $-NR^{13}SO_2R^{14}$, and $-NR^{13}SO_2$aryl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heteroaryl, aryl, and heterocyclyl are optionally substituted with at least one substituent $R^{16}$, or ($R^1$ and $R^2$), and /or ($R^3$ and $R^4$), and /or ($R^5$ and $R^6$), together with the ring to which they are attached, form a fused ring selected from heterocyclyl, and heteroaryl rings optionally substituted with at least one substituent $R^{16}$;

provided that $R^1$ is absent when Q is N, and $R^5$ is absent when W is N;

$R^7$ is selected from hydrogen, halogen, alkyl, -O-alkyl, and -S-alkyl;

$R^{12}$ is selected from hydrogen and alkyl;

$R^{13}$, $R^{14}$ and $R^{15}$, which may be the same or different, are each selected from H, haloalkyl, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl; or ($R^{13}$ and $R^{14}$), and /or ($R^{14}$ and $R^{15}$) together with the atom(s) to which they are attached, each form a ring selected from heterocyclyl, and heteroaryl rings optionally substituted with at least one substituent $R^{16}$;

$R^{16}$ is selected from halogen, haloalkyl, alkyl, alkenyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, alkynyl, oxo, -CN, -OR', -NR'R", -COR', $-CO_2R'$, -CONR'R", -C(=NR')NR"R'", -NR'COR", -NR'CONR'R", $-NR'CO_2R"$, $-SO_2R'$, $-SO_2$aryl, $-NR'SO_2NR"R'"$, $NR'SO_2R"$, and $-NR'SO_2$aryl, wherein R', R", and R'" are independently selected from H, haloalkyl, alkyl, alkenyl,

alkynyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl, or (R' and R"), and /or (R" and R'") together with the atoms to which they are attached, form a ring selected from heterocyclyl, and heteroaryl rings.

2. The at least one compound of claim 1, which is selected from compounds of Formula (II)



(II)

stereoisomers thereof, and pharmaceutically acceptable salts thereof,

wherein:

Q is selected from C and N;

X is selected from $CH_2$ and O;

Y is selected from $NR^{12}$, O, and S;

Z is selected from O, S, $NR^{13}$, CO, SO, $SO_2$, and $CR^{13}R^{14}$;

$R^1$, $R^2$, $R^3$, $R^4$, $R^8$, $R^9$, $R^{10}$ and $R^{11}$, which may be the same or different, are each selected from hydrogen, halogen, haloalkyl, alkyl, alkenyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, alkynyl, -CN, $-NR^{13}R^{14}$, $-OR^{13}$, $-COR^{13}$, $-CO_2R^{13}$, $-CONR^{13}R^{14}$, $-C(=NR^{13})NR^{14}R^{15}$, $-NR^{13}COR^{14}$, $-NR^{13}CONR^{14}R^{15}$, $-NR^{13}CO_2R^{14}$, $-SO_2R^{13}$, $-NR^{13}SO_2NR^{14}R^{15}$, and $-NR^{13}SO_2R^{14}$, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heteroaryl, aryl, and heterocyclyl are each optionally substituted with at least one substituents $R^{16}$, or ($R^1$ and $R^2$), and /or ($R^3$ and $R^4$), and /or ($R^8$ and $R^9$), and /or ($R^9$ and $R^{10}$), and /or ($R^{10}$ and $R^{11}$) together with the ring to which they are attached, form a fused ring selected from heterocyclyl, and heteroaryl rings optionally substituted with at least one substituent $R^{16}$; provided that $R^1$ is absent when Q is N;

$R^7$ is selected from hydrogen, halogen, alkyl, -O-alkyl, and -S-alkyl;

$R^{12}$ is selected from hydrogen and alkyl;

$R^{13}$, $R^{14}$ and $R^{15}$, which may be the same or different, are each selected from H, haloalkyl, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl; or ($R^{13}$ and $R^{14}$), and /or ($R^{14}$ and $R^{15}$) together with the atom(s) to which they are attached, each form a ring selected from heterocyclyl, and heteroaryl rings optionally substituted with at least one substituent $R^{16}$;

$R^{16}$ is selected from halogen, haloalkyl, alkyl, alkenyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, alkynyl, oxo, -CN, -OR', -NR'R", -COR', -$CO_2$R', -CONR'R", -C(=NR')NR"R"', -NR'COR", -NR'CONR'R", -NR'$CO_2$R", -$SO_2$R', -$SO_2$aryl, -NR'$SO_2$NR"R"', NR'$SO_2$R", and -NR'$SO_2$aryl, wherein R', R", and R"' are independently selected from H, haloalkyl, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl, or (R' and R"), and /or (R" and R"') together with the atoms to which they are attached, form a ring selected from heterocyclyl, and heteroaryl rings.

3. The at least one compound of claim 1, which is selected from compounds of Formula (III)



(III),

stereoisomers thereof, and pharmaceutically acceptable salts thereof,

wherein:

X is selected from $CH_2$ and O;

Z is selected from O, S, $NR^{13}$, CO, SO, $SO_2$, and $CR^{13}R^{14}$;

A is selected from -$CH_2$-, -$CH_2CH_2$-, -CH=CH-, =CH-, -$NR^{13}$-, -$CH_2$-O-, -O-, and -S-;

M is selected from =CH- and -C(O)-; or M is absent;

$R^1$, $R^2$, $R^8$, $R^9$, $R^{10}$ and $R^{11}$, which may be the same or different, are each selected from hydrogen, halogen, halo-alkyl, alkyl, alkenyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, alkynyl, -CN, -$NR^{13}R^{14}$, -$OR^{13}$, -$COR^{13}$, -$CO_2R^{13}$, -$CONR^{13}R^{14}$, -$C(=NR^{13})NR^{14}R^{15}$, -$NR^{13}COR^{14}$, -$NR^{13}CONR^{14}R^{15}$, -$NR^{13}CO_2R^{14}$, -$SO_2R^{13}$,-$SO_2$aryl, -$NR^{13}SO_2NR^{14}R^{15}$, and -$NR^{13}SO_2R^{14}$, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heteroaryl, aryl, and heterocyclyl are each optionally substituted with at least one substituent $R^{16}$,

or ($R^1$ and $R^2$), and /or ($R^8$ and $R^9$), and /or ($R^9$ and $R^{10}$), and /or ($R^{10}$ and $R^{11}$) together with the ring to which they are attached, form a fused ring selected from heterocyclyl, and heteroaryl rings optionally substituted with at least one substituent $R^{16}$;

$R^{12}$ is selected from hydrogen and alkyl;

$R^{13}$, $R^{14}$ and $R^{15}$, which may be the same or different, are each selected from H, haloalkyl, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl; or ($R^{13}$ and $R^{14}$), and /or ($R^{14}$ and $R^{15}$) together with the atom(s) to which they are attached, each form a ring selected from heterocyclyl, and heteroaryl rings optionally substituted with at least one substituent $R^{16}$;

$R^{16}$ is selected from halogen, haloalkyl, alkyl, alkenyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, alkynyl, oxo, -CN, -OR', -NR'R", -COR', -$CO_2$R', -CONR'R", -C(=NR')NR"R'", -NR'COR", -NR'CONR'R", -NR'$CO_2$R", -$SO_2$R', -$SO_2$aryl, -NR'$SO_2$NR"R'", NR'$SO_2$R", and -NR'$SO_2$aryl, wherein R', R", and R'" are independently selected from H, haloalkyl, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl, or (R' and R"), and /or (R" and R'") together with the atoms to which they are attached, form a ring selected from heterocyclyl, and heteroaryl rings.

4. The at least one compound of claim 1, which is selected from compounds of Formula (IV)



(IV),

stereoisomers thereof, and pharmaceutically acceptable salts thereof,

wherein:

B is selected from $CH_2$, O, and $NR^{13}$;

X is selected from $CH_2$ and O;

$R^1$, $R^2$, $R^8$, $R^9$, $R^{10}$ and $R^{11}$, which may be the same or different, are each selected from hydrogen, halogen, haloalkyl, alkyl, alkenyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, alkynyl, -CN, -$NR^{13}R^{14}$, -$OR^{13}$, -$COR^{13}$,-$CO_2R^{13}$, -$CONR^{13}R^{14}$,-$C(=NR^{13})NR^{14}R^{15}$, -$NR^{13}COR^{14}$, -$NR^{13}CONR^{14}R^{15}$, -$NR^{13}CO_2R^{14}$, -$SO_2R^{13}$,-$SO_2$aryl, -$NR^{13}SO_2NR^{14}R^{15}$, and -$NR^{13}SO_2R^{14}$,wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heteroaryl, aryl, and heterocyclyl are each optionally substituted with at least one substituent $R^{16}$, or ($R^1$ and $R^2$), and /or ($R^8$ and $R^9$), and /or ($R^9$ and $R^{10}$), and /or ($R^{10}$ and $R^{11}$) together with the ring to which they are attached, form a fused ring selected from heterocyclyl, and heteroaryl rings optionally substituted with at least one substituent $R^{16}$;

$R^{12}$ is selected from hydrogen and alkyl;

$R^{13}$, $R^{14}$ and $R^{15}$, which may be the same or different, are each selected from H, haloalkyl, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl; or ($R^{13}$ and $R^{14}$), and /or ($R^{14}$ and $R^{15}$) together with the atom(s) to which they are attached, each form a ring selected from heterocyclyl, and heteroaryl rings optionally substituted with at least one substituent $R^{16}$;

$R^{16}$ is selected from halogen, haloalkyl, alkyl, alkenyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, alkynyl, oxo, -CN, -OR', -NR'R", -COR', -$CO_2$R', -CONR'R", -C(=NR')NR"R'", -NR'COR", -NR'CONR'R", -NR'$CO_2$R", -$SO_2$R', -$SO_2$aryl, -NR'$SO_2$NR"R'", NR'$SO_2$R", and -NR'$SO_2$aryl, wherein R', R", and R'" are independently selected from H, haloalkyl, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl, or (R' and R"), and /or (R" and R'") together with the atoms to which they are attached, form a ring selected from heterocyclyl, and heteroaryl rings.

5. The at least one compound of claim 4, wherein $R^1$ and $R^2$, which may be the same or different, are each selected from hydrogen, alkyl, and halo.

6. The at least one compound of claim 4, wherein $R^{12}$ is H.

7. The at least one compound of claim 4, wherein X is O.

8. The at least one compound of claim 4, wherein X is $CH_2$.

9. The at least one compound of claim 4, wherein $R^8$, $R^9$, $R^{10}$, and $R^{11}$, which may be the same or different, are each selected from alkyl, hydrogen, haloalkyl, halogen, hydroxy, -CN, -Oalkyl, -Ohaloalkyl, and aryl.

10. The at least one compound of claim 4, wherein $R^8$, $R^9$, $R^{10}$, and $R^{11}$, which may be the same or different, are each selected from methyl, tert-butyl, hydrogen, -$CF_3$, halogen, hydroxy, -CN, methoxy, $OCF_3$, and phenyl.

11. The at least one compound of claim 1, which is selected from compounds of Formula (V)



(V),

stereoisomers thereof, and pharmaceutically acceptable salts thereof,

wherein:

X is selected from $CH_2$ and O;

$R^8$, $R^9$, $R^{10}$ and $R^{11}$, which may be the same or different, are each selected from hydrogen, halogen, alkyl, alkenyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, alkynyl, $-NR^{13}R^{14}$, $-OR^{13}$, $-COR^{13}$, $-CO_2R^{13}$, $-CONR^{13}R^{14}$, $-C(=NR^{13})NR^{14}R^{15}$, $-NR^{13}COR^{14}$, $-NR^{13}CONR^{14}R^{15}$, $-NR^{13}CO_2R^{14}$, $-SO_2R^{13}$,$-SO_2$aryl, $-NR^{13}SO_2NR^{14}R^{15}$, and $-NR^{13}SO_2R^{14}$, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heteroaryl, aryl, and heterocyclyl are each optionally substituted with at least one substituent $R^{16}$, or ($R^8$ and $R^9$), and /or ($R^9$ and $R^{10}$), and /or ($R^{10}$ and $R^{11}$) together with the ring to which they are attached, form a fused ring selected from heterocyclyl, and heteroaryl rings optionally substituted with at least one substituent $R^{16}$;

$R^{13}$, $R^{14}$ and $R^{15}$, which may be the same or different, are each selected from H, haloalkyl, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl; or ($R^{13}$ and $R^{14}$), and /or ($R^{14}$ and $R^{15}$) together with the atom(s) to which they are attached, each form a ring selected from heterocyclyl, and heteroaryl rings optionally substituted with at least one substituent $R^{16}$;

$R^{16}$ is selected from halogen, haloalkyl, alkyl, alkenyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, alkynyl, oxo, -CN, -OR', -NR'R", -COR', $-CO_2R'$, -CONR'R", -C(=NR')NR"R'", -NR'COR", -NR'CONR'R", $-NR'CO_2R"$, $-SO_2R'$, $-SO_2$aryl, $-NR'SO_2NR"R'"$, $NR'SO_2R"$, and $-NR'SO_2$aryl, wherein R', R", and R'" are independently selected from H, haloalkyl, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl, or (R' and R"), and /or (R" and R'") together with the atoms to which they are attached, form a ring selected from heterocyclyl, and heteroaryl rings.

12. At least one compound selected from the following compounds:
























































































stereoisomers thereof, and pharmaceutically acceptable salts thereof.

13. At least one compound selected from the following compounds:









stereoisomers thereof, and pharmaceutically acceptable salts thereof.

14. At least one compound of Claim 13, which is selected from the following compounds:













and pharmaceutically acceptable salts thereof.

15. The at least one compound of claim 1, having a Raf-inhibiting activity corresponding to a$IC_{50}$ of 10 μM or less in a Raf enzyme assay.

16. A pharmaceutical composition comprising at least one pharmaceutically acceptable carrier and as an active ingredient a therapeutically effective amount of at least one compound of any one of claim 1-15 or pharmaceutically acceptable salts thereof.

17. Use of at least one compound of any one of claims 1-15 or pharmaceutically acceptable salts thereof in the manufacture of a medicament for treating cancer responsive to inhibition of Raf kinase.

18. A method for making a medicament for inhibiting the activity of Raf kinase, comprising including into the medicament at least one compound of any one of claims 1-15 or pharmaceutically acceptable salts thereof.